CAT

Across TCGA pan-cancer cohorts, CAT Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CAT data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CAT Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CAT expression acts as an unfavorable survival marker.

LIHC, READ, and BLCA are the cancer types where CAT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	III,IV	0.076	0.360	.001	24	view →
READ	OS	Median	II,III,IV	0.054	0.934	<.001	18	view →
BLCA	OS	Median	III,IV	0.254	0.688	<.001	15	view →
HNSC	OS	Median	III,IV	0.203	0.745	.005	12	view →
KIRP	DFS	Median	All	0.133	0.605	.014	6	view →
COAD	OS	Median	III,IV	0.133	0.696	.019	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CAT–LIHC (DFS)

Open the LIHC breakdown →